Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial

R E Ratner; J Rosenstock; G Boka; DRI6012 Study Investigators; Timothy Lyons

doi:10.1111/j.1464-5491.2010.03020.x

Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial

R E Ratner, J Rosenstock, G Boka, DRI6012 Study Investigators, Timothy Lyons

School of Medicine, Dentistry and Biomedical Sciences

Research output: Contribution to journal › Article › peer-review

140 Citations (Scopus)

Abstract

To evaluate the dose-response relationship of lixisenatide (AVE0010), a glucagon-like peptide-1 (GLP-1) receptor agonist, in metformin-treated patients with Type 2 diabetes.

Original language	English
Pages (from-to)	1024-32
Number of pages	9
Journal	Diabetic Medicine
Volume	27
Issue number	9
DOIs	https://doi.org/10.1111/j.1464-5491.2010.03020.x
Publication status	Published - Sept 2010

Keywords

Adult
Aged
Blood Glucose
Diabetes Mellitus, Type 2
Dose-Response Relationship, Drug
Double-Blind Method
Drug Resistance
Female
Hemoglobin A, Glycosylated
Humans
Hypoglycemic Agents
Male
Metformin
Middle Aged
Peptides
Placebos
Receptors, Glucagon

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/j.1464-5491.2010.03020.x

Cite this

Ratner, R. E., Rosenstock, J., Boka, G., DRI6012 Study Investigators, & Lyons, T. (2010). Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial. Diabetic Medicine, 27(9), 1024-32. https://doi.org/10.1111/j.1464-5491.2010.03020.x

@article{8c4742a374fc42f5a6ba1341bc7568b4,

title = "Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial",

abstract = "To evaluate the dose-response relationship of lixisenatide (AVE0010), a glucagon-like peptide-1 (GLP-1) receptor agonist, in metformin-treated patients with Type 2 diabetes.",

keywords = "Adult, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Double-Blind Method, Drug Resistance, Female, Hemoglobin A, Glycosylated, Humans, Hypoglycemic Agents, Male, Metformin, Middle Aged, Peptides, Placebos, Receptors, Glucagon",

author = "Ratner, {R E} and J Rosenstock and G Boka and {DRI6012 Study Investigators} and Timothy Lyons",

year = "2010",

month = sep,

doi = "10.1111/j.1464-5491.2010.03020.x",

language = "English",

volume = "27",

pages = "1024--32",

journal = "Diabetic Medicine",

issn = "0742-3071",

publisher = "Wiley-Blackwell",

number = "9",

}

Ratner, RE, Rosenstock, J, Boka, G, DRI6012 Study Investigators & Lyons, T 2010, 'Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial', Diabetic Medicine, vol. 27, no. 9, pp. 1024-32. https://doi.org/10.1111/j.1464-5491.2010.03020.x

Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial. / Ratner, R E; Rosenstock, J; Boka, G et al.
In: Diabetic Medicine, Vol. 27, No. 9, 09.2010, p. 1024-32.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin

T2 - a randomized, double-blind, placebo-controlled trial

AU - Ratner, R E

AU - Rosenstock, J

AU - Boka, G

AU - DRI6012 Study Investigators

AU - Lyons, Timothy

PY - 2010/9

Y1 - 2010/9

N2 - To evaluate the dose-response relationship of lixisenatide (AVE0010), a glucagon-like peptide-1 (GLP-1) receptor agonist, in metformin-treated patients with Type 2 diabetes.

AB - To evaluate the dose-response relationship of lixisenatide (AVE0010), a glucagon-like peptide-1 (GLP-1) receptor agonist, in metformin-treated patients with Type 2 diabetes.

KW - Adult

KW - Aged

KW - Blood Glucose

KW - Diabetes Mellitus, Type 2

KW - Dose-Response Relationship, Drug

KW - Double-Blind Method

KW - Drug Resistance

KW - Female

KW - Hemoglobin A, Glycosylated

KW - Humans

KW - Hypoglycemic Agents

KW - Male

KW - Metformin

KW - Middle Aged

KW - Peptides

KW - Placebos

KW - Receptors, Glucagon

U2 - 10.1111/j.1464-5491.2010.03020.x

DO - 10.1111/j.1464-5491.2010.03020.x

M3 - Article

C2 - 20722676

SN - 0742-3071

VL - 27

SP - 1024

EP - 1032

JO - Diabetic Medicine

JF - Diabetic Medicine

IS - 9

ER -

Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this